Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000346847 | SCV000365734 | uncertain significance | PTEN hamartoma tumor syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000482560 | SCV000565442 | uncertain significance | not provided | 2016-07-22 | criteria provided, single submitter | clinical testing | This variant, denoted PTEN c.-29_-27delCCT, is a deletion of 3 nucleotides upstream of the PTEN ATG translational start site in the 5' untranslated region (UTR). The surrounding sequence, with the bases that are deleted in braces, is TCCT[CCT]TTTTC. This variant has not, to our knowledge, been published in the literature as pathogenic or benign and does not appear to affect the start codon or the Kozak translational consensus sequence. PTEN c.-29_-27delCCT was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Based on currently available information, it is unclear whether PTEN c.-29_-27delCCT is pathogenic or benign. We consider it to be a variant of uncertain significance. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000482560 | SCV004219133 | uncertain significance | not provided | 2024-10-18 | criteria provided, single submitter | clinical testing | The PTEN c.-29_-27del variant has not been reported in individuals with PTEN-related conditions in the published literature. The frequency of this variant in the general population, 0.000044 (5/113736 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Based on the available information, we are unable to determine the clinical significance of this variant. |
Fulgent Genetics, |
RCV005044559 | SCV005678969 | uncertain significance | Macrocephaly-autism syndrome; Familial meningioma; Glioma susceptibility 2; Familial prostate cancer; Cowden syndrome 1 | 2024-01-10 | criteria provided, single submitter | clinical testing |